Acomhal Research, Inc.

Roanoke, VA · Biotech · Private

Therapeutics targeting connexin43 localization to inhibit epithelial-mesenchymal transition in triple-negative breast cancer

Claim this profile

Follows are private to you and power your alerts

Updated · acomhal.com

Sector
Biotech
Headquarters
Roanoke, VA
Latest Form D
$300K, Apr 2021
Total capital
$1.1M
Federal grants
$850K
3 awards · 2017–2020
Rank in peer group#243 of 326
Private capital raised
$300K
1 Form D · last Apr 2021
66 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20172018201920202021FEDERAL ↑EQUITY ↓Cumulative $1.1M$225K$225K$400K1st Form D$300K
20172018201920202021FEDERAL ↑EQUITY ↓Cumulative $1.1M$225K$225K$400K1st Form D$300K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$300K
  • Federal grantHealth and Human S · Phase I · Inhibition of breast cancer cell metastases using a connexin43 mimetic peptide$400K
  • Federal grantHealth and Human S · Phase I · Therapeutic disruption of Connexin mediated microtubule regulation to target glioblastoma cancer stem cells$225K
  • Federal grantHealth and Human S · Phase I · Therapeutic disruption of Connexin43-mediated microtubule regulation to target glioblastoma cancer stem cells$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

44months

from Acomhal Research, Inc.’s first federal award to its first private round.

First federal award · Aug 2017
Health and Human S · $225K
First Form D · Apr 2021
$300K · 1st Form D
Awards before first raise
3 awards

An association in public records, not a cause or a prediction.

Standing among 326 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Samy LamouilleResearcherExecutive Officer, DirectorLinked by $625K in grants as PI
  • Craig RameyDirectorNamed in SEC Form D filings
  • Robert GourdieExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • FirstString Research, IncShares a founder: SAMY LAMOUILLE
  • Inozyme PharmaSimilar federal contract value in Biotech · null in contracts
  • Encepheal Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • PELICAN THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • ZUCHEM INC.Similar federal contract value in Biotech · null in contracts
  • Deepcell, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .